To test the impact of anti-B7 mAbs on de novo priming of CD8 T cells in peripheral lymphoid organs, we immunized tumor-bearing mice with SIY peptide and treated the mice with Ipilimumab in the presence or absence of anti-B7 mAbs. The gene discussed is CD8A; the disease is neoplasm.